Display Settings:

Format

Send to:

Choose Destination
Regul Toxicol Pharmacol. 2013 Mar;65(2):278-85. doi: 10.1016/j.yrtph.2012.12.006. Epub 2012 Dec 29.

Performance standards and alternative assays: practical insights from skin sensitization.

Author information

  • 1BASF SE, Experimental Toxicology and Ecology, Ludwigshafen, Germany. susanne.kolle@basf.com

Abstract

To encourage the development and validation of alternative toxicity test methods, the effort required for validation of test methods proposed for regulatory purposes should be minimized. Performance standards (PS) facilitate efficient validation by requiring limited testing. Based on the validated method, PS define accuracy and reliability values that must be met by the new similar test method. The OECD adopted internationally harmonized PS for evaluating new endpoint versions of the local lymph node assay (LLNA). However, in the process of evaluating a lymph node cell count alternative (LNCC), simultaneous conduct of the regulatory LLNA showed that this standard test may not always perform in perfect accord with its own PS. The LNCC results were similar to the concurrent LLNA. Discrepancies between PS, LLNA and LNCC were largely associated with "borderline" substances and the variability of both endpoints. Two key lessons were learned: firstly, the understandable focus on substances close to the hazard classification borderline are more likely to emphasise issues of biological variability, which should be taken into account during the evaluation of results; secondly, variability in the results for the standard assay should be considered when selecting reference chemicals for PS.

Copyright © 2013 Elsevier Inc. All rights reserved.

PMID:
23279805
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk